Advertisement

Topics

GUERBET : Revenue at June 30, 2016: EU376.7 million, up 65.7%

20:00 EDT 27 Jul 2016 | Globe Newswire

 Change in pro forma revenue*: - 5.3%
Change in pro forma revenue* at constant exchange rates: - 2.3%

Villepinte, France, July 28, 2016 (GLOBE NEWSWIRE) -- Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €376.7 million for the 1st half of 2016, up 65.7% from 2015. This increase incorporates an adverse exchange rate impact of €11.9 million, mainly on the Brazilian real, Argentine peso, Korean won, and the Turkish lira. At constant exchange rates, the Group posted sales of €388.6 million, slightly down 2.3% from the pro forma revenue for the first half of 2015.

Consolidated Group revenue (IFRS)

In millions of € 1st half 2016   1st half 2015
pro forma* 
Change   1st half 2015 reported Change
Sales - Europe 189,7   187,5 +1.2%   158,7 +19.5%
Sales - Other Markets 187,0   210,3 -11,1%   68,6 +172.6%
Total 376,7   397,8 -5,3%   227,3 +65.7%

*: Integration of CMDS activities

Good performance level in Europe
In Europe, consolidated revenue for the first half totaled €189.7 million compared with €187.5 million for 2015 in its pro forma version, incorporating an adverse exchange rate impact of nearly €2 million. At current exchange rates, the second quarter confirmed the growth of the first quarter, which was already 1.2%.

Outside Europe, despite the good performance of Dotarem® in the US, the Group's sales totaled €187.0 million compared with €210.3 million for 2015 in its pro forma version, an 11.1% decrease.  However, this decline incorporates an adverse exchange rate impact of nearly €10 million and reveals an improving trend in the second quarter (-9.0%), at current exchange rates, compared with the first quarter (-13.1%).

Double-digit growth in Dotarem® sales, lower performance for X-rays
At constant exchange rates, the activity breaks down as follows: 

  • good Dotarem sales in both Europe and the US resulted in half-year revenue of €121.8 million for MRI, up 5.5%
  • the X-ray segment fell by 6.8% to €205.3 million, mainly due to Optiray, but its decline began to slow down in the second quarter thanks to stimulus actions undertaken since the acquisition of CMDS
  • the performance of Lipiodol® and Patent Blue V increased the IRT segment's revenue by 18.3% to €25.4 million
  • lastly, the Imaging Solutions and Services (ISS) segment is down nearly 7.4% with revenue of €34.5 million, reflecting lower injector sales.

2016 outlook: stabilization of sales at +/- 3% already achieved and confirmation of annual targets
The second quarter confirms Guerbet's ability to reverse the trend on sharply declining CMDS sales (-20% over the last two years before the acquisition). At the end of the first half, consolidated sales are -2.3% at constant exchange rates, within the target window of +/- 3% announced for the full year. The Group is therefore confirming its annual targets and its ability to start growing again in 2017.

Upcoming events:

Publication of 2016 half-year earnings: September 28, 2016, before trading

About Guerbet

Guerbet is a pioneer in the contrast agent field, with nearly 90 years' experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI), and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 9% of its sales each year. Guerbet (GBT) is listed on Euronext Paris (Segment B - Mid Caps) and generated revenue of €489 million in 2015.    

For more information about Guerbet, please visit www.guerbet.com

Contacts

Guerbet Actifin
Jean-François Le Martret
Chief Financial Officer
01 45 91 50 00

 

 

 

 
Financial Communications
Benjamin Lehari
01 56 88 11 25
blehari@actifin.fr

 

Press
Jennifer Jullia
01 56 88 11 19
jjullia@actifin.fr

 

Press release http://hugin.info/159769/R/2031561/755976.pdf

HUG#2031561

NEXT ARTICLE

More From BioPortfolio on "GUERBET : Revenue at June 30, 2016: EU376.7 million, up 65.7%"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Radiology
Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...